IKT inhibikase.com: Accounting Capitalization

Inhibikase Therapeutics, Inc. (IKT) - corporate logo

Inhibikase Therapeutics (IKT) organizes the precise transport of biomaterials for dementia research, while the development of unique Alzheimer's disease treatments will provide the company with dominant pricing power. This price chart captured the indicator at 0.15. Currently, kinase inhibitor research centers are operating at full capacity, and sterile rooms and chromatographic equipment are being regularly modernized.

Inhibikase (IKT): Company Net Assets from 07/04/2022 to 10/30/2026

IKT (Inhibikase Therapeutics, Inc.): analytical breakdowns and indicator data

- stock price and consensus target price:
Price Inhibikase Pharma|IKT - Price Target Chart
- company stock capitalization data:
Market Capitalization Inhibikase Therapeutics Inc|IKT - Enterprise Value
- book capitalization indicators:
Net Asset Value per Share Inhibikase Therapeutics|IKT - Company Net Assets|Market Capitalization to Book Value Ratio inhibikase.com|IKT - Aggregate Company Assets
- company total debt and liquidity indicators:
All Debt to Shareholders' Equity Ratio Inhibikase Therapeutics|IKT - Long-Term Debt to Equity|Current Liabilities to Capital Inhibikase Therapeutics Inc|IKT - Company Aggregate Debts|Debts to Net Assets Inhibikase Therapeutics Inc|IKT - Company Long-Term Debt|Company Short-Term Indebtedness Inhibikase Therapeutics|Intermediate Coverage Ratio inhibikase.com
- net income and valuation ratios data:
IKT - Net Profit
Fundamental company valuation:IKT (Inhibikase Pharma)
Product sample of Inhibikase Therapeutics

Book value capitalization reflects the real value of Inhibikase Therapeutics (IKT) net assets, excluding market speculation. Analyzing this metric allows for an assessment of the business's fundamental stability and the risk of stock overvaluation. The book value capitalization financial indicator reveals the gap between the exchange rate and actual capital. For Inhibikase Therapeutics (IKT), this metric is critical while awaiting Phase 2 clinical trial results. The success of the Parkinson's disease therapy could drastically alter the intrinsic value of the assets.

Competitor analysis

Biogen Idec - Total Net Assets|Neurocrine Biosciences (NBIX) - Company Book Value|Accounting Capitalization RGC|AXSM (Axsome Therapeutics, Inc.) - Book Capitalization|Total Stockholders' Equity ACADIA Pharma ACAD|Company Net Assets XENE (Xenon Pharmaceuticals Inc)|Book Capitalization Viking Therapeutics Corp (VKTX)|Company Book Value Supernus Pharmaceuticals SUPN|Accounting Value of Company CPRX|DNLI - Company Book Value|Total Stockholders' Equity Harmony Biosciences Inc|BHVN: Book Capitalization|AMLX - Book Valuation of Business|Company Book Value Trevi Therapeutics|Accounting Capitalization PRAX (praxismedicines.com)|Book Capitalization AVXL|CBLL (CeriBell Inc) - Accounting Value of Company|Book Capitalization PRTA (prothena.com)|Book Valuation of Business Alector Inc. (ALEC)|Annexon, Inc. - Book Capitalization|OMER: Company Book Value|NGNE: Book Capitalization|ACIU - Book Valuation of Business|Company Book Value Voyager Pharma|Book Capitalization Neumora Corp|Book Capitalization SCLX|Book Capitalization tevogen.com (TVGN)|Company Book Value Alpha Cognition Inc. ACOG|Book Valuation of Business cogrx.com (CGTX)|Cassava - Book Capitalization|Total Stockholders' Equity Assertio Holdings, Inc.|COYA (coyatherapeutics.com) - Company Net Assets|Vistagen - Accounting Value of Company|Company Net Assets OVID|ABOS (Acumen Pharmaceuticals Inc.) - Total Net Assets|Book Capitalization CRVO|ATHE (alteritytherapeutics.com) - Accounting Value of Company|Book Capitalization CLNN (Clene)|PepGen Inc (PEPG) - Total Stockholders' Equity|JUNS - Company Book Value|Accounting Value of Company RLMD (Relmada Therapeutics Inc)|ANVS: Book Capitalization|Grace Therapeutics (GRCE) - Book Capitalization|Company Book Value Firefly Neuroscience, Inc|ANEW Medical, Inc. - Net Asset Value|Book Capitalization NRSN|RVPH - Total Stockholders' Equity|MetaVia - Company Net Assets|Book Capitalization NeurAxis Inc NRXS|HSDT: Company Net Assets|Passage Bio, Inc. - Total Net Assets|NEUP: Book Capitalization|NERV - Book Valuation of Business|ATHA (Athira) - Book Capitalization|Company Net Assets Addex (ADXN)|Company Book Value Alzamend Neuro, Inc. (ALZN)|Book Valuation of Business cyclerion.com|Book Capitalization PTIX (Protagenic Therapeutics, Inc.)|Book Valuation of Business Pasithea Therapeutics Corp (KTTA)|CRGT - Company Book Value|ATXI - Book Capitalization|BCLI (Brainstorm Cell) - Company Net Assets|CARA: Total Net Assets|Company Book Value Chromocell Therapeutics Corp.|Accounting Capitalization ELYM (Eliem)|Book Capitalization ITCI|LBPH - Total Stockholders' Equity|Marinus Pharmaceuticals - Company Net Assets|Book Capitalization nkgenbiotech.com NKGN|NRBO - Company Book Value|Accounting Value of Company SAGE (Sage Therapeutics Inc.)|Neurotrope (SNPX) - Company Book Value|Total Stockholders' Equity Trevena Inc (TRVN)|VIGL (Vigil Neuroscience Inc.) - Book Capitalization|Anew Medical Inc. (WENA) - Book Valuation of Business|Company Book Value Cerevel Therapeutics, Inc. (CERE)